NASDAQ$HALO
Halozyme Therapeutics Inc · Q4 2020 earnings
Q4 2020 earnings · · Investor relations
Briefing
Reported fourth quarter revenue of $121.7 million and earnings per share of $0.50.
Halozyme reported a successful fourth quarter, driven by the launch of DARZALEX® SC with ENHANZE®. The company transitioned to a profitable, high-growth company with strong prospects for continued growth.
- Fourth quarter revenue was $121.7 million, compared to $53.7 million for the fourth quarter of 2019.
- Earnings per share for the fourth quarter was $0.50, compared to a net loss in the fourth quarter of 2019 of $0.24 per share.
- Operating income for the fourth quarter was $77.6 million, compared to an operating loss of $32.1 million in the fourth quarter of 2019.
- Royalties increased by 86% compared to the prior year period, driven by the strong DARZALEX FASPRO® launch.
Headline financials
Revenue & EPS history
Halozyme · Revenue · Quarterly
$122M
Revenue by segment
Halozyme · $89.2M total across 2 segments · Q4 2020
- Revenues under collaborative agreements$57.3M+316.6%64.1%
- Royalties$32M+85.7%35.9%
Forward guidance
Halozyme expects revenues of $375 million to $395 million, representing year-over-year growth of 40%-48%, with revenues from royalties projected to approximately double versus 2020; Operating Income of $215 million to $235 million, representing year-over-year growth of 49%-63%; Earnings per share on a GAAP basis of $1.40 to $1.55, representing year-over-year growth of 54%-70%.
Tailwinds
- Revenues of $375 million to $395 million, representing year-over-year growth of 40%-48%
- Revenues from royalties projected to approximately double versus 2020
- Operating Income of $215 million to $235 million, representing year-over-year growth of 49%-63%
- Earnings per share on a GAAP basis of $1.40 to $1.55, representing year-over-year growth of 54%-70%
- The Company plans to repurchase up to $125 million in common stock during 2021 as part of the $550 million three-year share repurchase plan authorized by Halozyme’s board of directors in 2019.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q4 2020
+1.8%
Avg return
Earnings day
+4.4%
Avg return
5 days after
+1.8%
Avg return
30 days after
62%
32 / 52 earnings
Positive
+18.2%
Q1 2025
Best reaction
-12.8%
Q3 2015
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +2.7% | +1.1% | +6.5% | |
| Q4 2025 | -9.0% | -12.2% | -21.2% | |
| Q3 2025 | +2.7% | +3.1% | -4.9% | |
| Q1 2025 | +18.2% | +12.1% | -8.6% | |
| Q3 2024 | +13.0% | +16.1% | -4.7% | |
| Q2 2024 | +3.9% | +5.9% | +17.2% | |
| Q1 2024 | +2.8% | +5.6% | +25.9% | |
| Q4 2023 | +6.3% | +12.4% | +11.4% | |
| Q3 2023 | +9.1% | +4.7% | +12.3% | |
| Q2 2023 | +1.5% | +4.1% | -6.8% | |
| Q1 2023 | +13.9% | +8.9% | +12.8% | |
| Q4 2022 | +0.1% | -1.0% | -32.7% | |
| Q3 2022 | +7.4% | +16.6% | +25.0% | |
| Q2 2022 | -2.1% | -4.2% | -11.9% | |
| Q1 2022 | +3.3% | +8.2% | +20.4% | |
| Q4 2021 | +3.1% | +8.6% | +18.3% | |
| Q3 2021 | +2.6% | +4.3% | -15.0% | |
| Q2 2021 | +1.8% | +2.4% | +3.8% | |
| Q1 2021 | -10.3% | -9.5% | -17.2% | |
| Q4 2020 | +5.7% | -7.1% | -15.2% | |
| Q3 2020 | +12.9% | +34.6% | +45.2% | |
| Q2 2020 | -2.7% | -3.7% | -3.2% | |
| Q1 2020 | +0.2% | +2.7% | -1.4% | |
| Q4 2019 | -4.7% | -10.4% | -22.4% | |
| Q3 2019 | +6.4% | +13.9% | +12.8% | |
| Q2 2019 | -0.9% | -5.1% | -5.3% | |
| Q1 2019 | -3.1% | -5.9% | -10.9% | |
| Q4 2018 | -0.4% | +1.8% | -8.2% | |
| Q3 2018 | +0.7% | +0.6% | -1.6% | |
| Q2 2018 | +0.3% | -2.6% | +2.5% | |
| Q1 2018 | -7.3% | -3.0% | -7.2% | |
| Q4 2017 | +3.8% | +7.2% | +9.9% | |
| Q3 2017 | +12.2% | +6.9% | +11.5% | |
| Q2 2017 | -4.0% | -9.7% | -0.7% | |
| Q1 2017 | -1.6% | +3.1% | -7.3% | |
| Q4 2016 | +0.2% | +5.6% | +1.2% | |
| Q3 2016 | +14.2% | +48.7% | +33.7% | |
| Q2 2016 | -0.4% | +1.6% | +6.2% | |
| Q1 2016 | +3.7% | — | — | |
| Q4 2015 | +5.9% | — | — | |
| Q3 2015 | -12.8% | — | — | |
| Q2 2015 | -1.4% | — | — | |
| Q1 2015 | +2.8% | — | — | |
| Q4 2014 | +1.1% | — | — | |
| Q3 2014 | -3.3% | — | — | |
| Q2 2014 | +1.7% | — | — | |
| Q3 2010 | -1.4% | — | — | |
| Q3 2011 | -1.4% | — | — | |
| Q2 2010 | -3.3% | — | — | |
| Q2 2011 | -3.3% | — | — | |
| Q1 2011 | +5.2% | — | — | |
| Q1 2010 | -2.9% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro